LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

Search

Exact Sciences Corp

Fermé

SecteurSoins de santé

103.34 0.05

Résumé

Variation du prix de l'action

24h

Actuel

Min

102.91

Max

103.41

Chiffres clés

By Trading Economics

Revenu

-188M

-208M

Ventes

28M

878M

BPA

-0.21

Marge bénéficiaire

-23.674

Employés

7,100

EBITDA

-68M

-20M

Recommandations

By TipRanks

Recommandations

Neutre

Prévisions sur 12 Mois

+0.32% upside

Dividendes

By Dow Jones

Prochains Résultats

30 avr. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-15M

20B

Ouverture précédente

103.29

Clôture précédente

103.34

Sentiment de l'Actualité

By Acuity

100%

0%

338 / 351 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Strong Bullish Evidence

Exact Sciences Corp Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

22 janv. 2026, 18:36 UTC

Résultats
Principaux Mouvements du Marché

Abbott Laboratories Raised Prices, Prompting Sales Slump -- Update

22 janv. 2026, 13:23 UTC

Résultats
Principaux Mouvements du Marché

Abbott Laboratories 4Q Sales Grow, Outlook Underwhelms

20 nov. 2025, 13:14 UTC

Acquisitions, Fusions, Rachats

Correction to Abbott to Acquire Exact Sciences for $21 Billion Article

20 nov. 2025, 13:11 UTC

Acquisitions, Fusions, Rachats

Abbott to Acquire Exact Sciences for $21 Billion -- Update

20 nov. 2025, 12:55 UTC

Acquisitions, Fusions, Rachats

Abbott to Acquire Exact Sciences for $21 Billion

20 nov. 2025, 16:51 UTC

Acquisitions, Fusions, Rachats

Abbott Laboratories Will Buy Cologuard Maker Exact Sciences for $21 Billion -- Barrons.com

20 nov. 2025, 15:08 UTC

Acquisitions, Fusions, Rachats

Abbott to Acquire Exact Sciences for $21 Billion -- 4th Update

20 nov. 2025, 14:39 UTC

Market Talk
Acquisitions, Fusions, Rachats

Abbott and Exact Sciences Should Make a Good Fit -- Market Talk

20 nov. 2025, 14:30 UTC

Market Talk
Acquisitions, Fusions, Rachats

Exact Sciences Should Give Abbott's Diagnostics Business a Needed Boost -- Market Talk

20 nov. 2025, 13:51 UTC

Acquisitions, Fusions, Rachats

Abbott to Acquire Exact Sciences for $21 Billion -- 3rd Update

20 nov. 2025, 13:25 UTC

Acquisitions, Fusions, Rachats

Abbott to Acquire Exact Sciences for $21 Billion -- 2nd Update

20 nov. 2025, 13:24 UTC

Acquisitions, Fusions, Rachats

Exact Sciences Stock Soars. Abbott Is Buying It in Deal Valued at $21 Billion. -- Barrons.com

20 nov. 2025, 12:59 UTC

Acquisitions, Fusions, Rachats

Correction to Abbott to Acquire Exact Sciences for $21B Article

20 nov. 2025, 12:58 UTC

Acquisitions, Fusions, Rachats

Exact Sciences Stock Soars. Abbott Is Buying It in Deal Valued at $21 Billion. -- Barrons.com

20 nov. 2025, 12:56 UTC

Acquisitions, Fusions, Rachats

Abbott to Acquire Exact Sciences for $21B -- Update

20 nov. 2025, 12:54 UTC

Acquisitions, Fusions, Rachats

Abbott Labs: Expect to Maintain Investment-Grade Credit Rating >ABT EXAS

20 nov. 2025, 12:53 UTC

Acquisitions, Fusions, Rachats

Abbott Labs to Fund Exact Sciences Deal With Cash on Hand, Debt Financing >ABT EXAS

20 nov. 2025, 12:53 UTC

Acquisitions, Fusions, Rachats

Abbott Labs Sees Exact Sciences Deal Adding to Adjusted EPS in 2028, Beyond >ABT EXAS

20 nov. 2025, 12:53 UTC

Acquisitions, Fusions, Rachats

Abbott Labs Sees Exact Sciences Deal Cutting Adjusted EPS by 20c in 2026, 16c in 2027 >ABT EXAS

20 nov. 2025, 12:52 UTC

Acquisitions, Fusions, Rachats

Abbott Labs Sees at Least $100 Million Annual Pretax Synergies From Exact Sciences Deal by 2028 >ABT EXAS

20 nov. 2025, 12:46 UTC

Acquisitions, Fusions, Rachats

Exact Sciences Stock Soars. Abbott Is Buying It in Deal Valued at $21 Billion. -- Barrons.com

20 nov. 2025, 12:40 UTC

Acquisitions, Fusions, Rachats

Abbott to Acquire Exact Sciences for $21B

20 nov. 2025, 12:33 UTC

Acquisitions, Fusions, Rachats

Abbott Labs: Exact Sciences Deal Has Enterprise Value of About $23 Billion >ABT EXAS

20 nov. 2025, 12:33 UTC

Acquisitions, Fusions, Rachats

Exact Sciences to Be Acquired for $105/Share; Closed Wednesday at $86.18 >ABT EXAS

20 nov. 2025, 12:32 UTC

Acquisitions, Fusions, Rachats

Abbott Labs Sees Acquisition Immediately Adding to Revenue Growth, Gross Margin >ABT EXAS

20 nov. 2025, 12:31 UTC

Acquisitions, Fusions, Rachats

Abbott Labs: Exact Sciences Deal Has Total Equity Value of About $21 Billion >ABT EXAS

20 nov. 2025, 12:30 UTC

Acquisitions, Fusions, Rachats

Abbott to Buy Exact Sciences for $105/Share >ABT EXAS

20 nov. 2025, 12:30 UTC

Acquisitions, Fusions, Rachats

Abbott To Acquire Exact Sciences, A Leader In Large And Fast-growing Cancer Screening And Precision Oncology Diagnostics Segments >ABT

19 nov. 2025, 21:27 UTC

Acquisitions, Fusions, Rachats

Exact Sciences Stock Jumps on Reported Deal Interest from Abbott Laboratories -- Barrons.com

Comparaison

Variation de prix

Exact Sciences Corp prévision

Objectif de Prix

By TipRanks

0.32% hausse

Prévisions sur 12 Mois

Moyen 103.57 USD  0.32%

Haut 105 USD

Bas 85 USD

Basé sur 19 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

19 ratings

0

Achat

19

Maintien

0

Vente

Score Technique

By Trading Central

45.6 / 54.37Support & Résistance

Court Terme

Strong Bullish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

338 / 351Classement par Soins de santé

Sentiment de l'Actualité

Très Fortes Indications Baissières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Exact Sciences Corp

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
help-icon Live chat